Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut.
Dermatology Medical Oncology, Brown University/Legoretta Cancer Center, Providence, Rhode Island.
J Am Acad Dermatol. 2024 Dec;91(6):1177-1188. doi: 10.1016/j.jaad.2024.08.036. Epub 2024 Aug 23.
Antibody-drug conjugates (ADCs) are a new and emerging category of oncologic treatments that combine the target specificity of a monoclonal antibody with a cytotoxic payload. These drugs are associated with unique cutaneous toxicities that vary across agents. Currently, there are eleven ADCs with regulatory approval for solid and liquid tumors and over 80 ADCs currently in clinical development, it is critical for dermatologists to recognize and appropriately mitigate the cutaneous toxicities associated with these therapies. This clinical review will summarize the novel mechanisms and indications of approved ADCs, discuss dermatologic toxicities demonstrated in clinical trials and postmarketing studies, and impart recognition and management guidance when encountering these reactions to help maintain patients safely and comfortably on their medications.
抗体药物偶联物（ADCs）是一种新型的肿瘤治疗药物，结合了单克隆抗体的靶向特异性和细胞毒性有效载荷。这些药物与独特的皮肤毒性相关，不同药物之间存在差异。目前，已有 11 种 ADC 获得了用于实体瘤和液体肿瘤的监管批准，并且有超过 80 种 ADC 正在进行临床开发，皮肤科医生识别和适当减轻这些治疗相关的皮肤毒性至关重要。本临床综述将总结已批准 ADC 的新型机制和适应证，讨论临床试验和上市后研究中显示的皮肤毒性，并在遇到这些反应时提供识别和管理指导，以帮助患者安全、舒适地维持药物治疗。
